{"id":468986,"date":"2021-03-31T16:04:28","date_gmt":"2021-03-31T20:04:28","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=468986"},"modified":"2021-03-31T16:04:28","modified_gmt":"2021-03-31T20:04:28","slug":"opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/","title":{"rendered":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose"},"content":{"rendered":"
\n

SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of\u00a0$1.8 million\u00a0from the total grant of approximately\u00a0$7.4 million\u00a0from the National Institute on Drug Abuse\u00a0(\u201cNIDA\u201d), part of the National Institutes of Health (\u201cNIH\u201d), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03.<\/p>\n

With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1<\/sup>,\u00a0NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose deaths2<\/sup>.<\/p>\n

\u201cThe award of the final tranche of NIDA\u2019s grant validates the progress we are making to develop OPNT003 for submission to the FDA,\u201d said\u00a0Roger Crystal, M.D., President and CEO, Opiant Pharmaceuticals. \u201cIf approved, we believe OPNT003 can make a meaningful contribution to the NIH strategy identifying scientific solutions and novel pharmacotherapies to save lives from opioid overdose, particularly in the face of more powerful and potentially dangerous synthetic opioids, such as fentanyl.\u201d<\/p>\n

The Company also announced that Dr. Crystal will participate in a panel presentation entitled, \u201cConfronting the Opioid Crisis in the Age of Fentanyl and the Coronavirus Pandemic,\u201d at the Rx Drug Abuse and Heroin Summit taking place virtually April 5-9, 2021. The panel will take place on April 6 from 2-3 p.m., EST. Further details are available at:\u00a0
https:\/\/www.eventscribe.com\/2021\/RxSummit2021\/agenda.asp?startdate=4\/6\/2021&enddate=4\/6\/2021&BCFO=&pfp=Browse%20by%20Day&tn=&cpf2=&cus2=&pta=<\/p>\n

In addition to the grant from NIDA, the development of OPNT003 is supported by a contract with the\u00a0Biological Advance Research and Development Agency.<\/p>\n

\n About\u00a0Opiant Pharmaceuticals, Inc.\u00a0<\/strong>
\n
Opiant Pharmaceuticals, Inc., the company that developed NARCAN\u00ae<\/sup> Nasal Spray, is building a leading\u00a0franchise\u00a0of new medicines to combat addictions and drug overdose. For more information, visit:\u00a0www.opiant.com<\/a>.<\/p>\n

\n
\n Forward-Looking Statements<\/em>
\n <\/strong>
\n
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. Additional factors that could materially affect actual results can be found in our Form 10-K for the year ended\u00a0December 31, 2020, filed with the\u00a0Securities and Exchange Commission\u00a0on\u00a0March 4, 2021, including under the caption titled “Risk Factors.” These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.<\/p>\n

\n References<\/strong>\n <\/p>\n

    \n
  1. Centers for Disease Control and Prevention. Provisional Drug Overdose Death Counts.\u00a0March 8 , 2021. Retrieved from\u00a0https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm<\/a>.<\/li>\n
  2. Volkow, N., Collins, F. The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017. 377:391-394<\/li>\n<\/ol>\n

    For Media and Investor Inquiries:
    Ben Atkins, Opiant
    (310) 598-5410
    batkins@opiant.com<\/a><\/p>\n


    \n
    \n \n <\/div>\n

    <\/div>\n","protected":false},"excerpt":{"rendered":"

    SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of\u00a0$1.8 million\u00a0from the total grant of approximately\u00a0$7.4 million\u00a0from the National Institute on Drug Abuse\u00a0(\u201cNIDA\u201d), part of the National Institutes of Health (\u201cNIH\u201d), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1,\u00a0NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose … <\/p>\n

    Continue reading “Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-468986","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOpiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of\u00a0$1.8 million\u00a0from the total grant of approximately\u00a0$7.4 million\u00a0from the National Institute on Drug Abuse\u00a0(\u201cNIDA\u201d), part of the National Institutes of Health (\u201cNIH\u201d), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1,\u00a0NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose … Continue reading "Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-31T20:04:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose\",\"datePublished\":\"2021-03-31T20:04:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/\"},\"wordCount\":665,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/\",\"name\":\"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=\",\"datePublished\":\"2021-03-31T20:04:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/","og_locale":"en_US","og_type":"article","og_title":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk","og_description":"SANTA MONICA, Calif., March 31, 2021 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc.\u00a0(\u201cOpiant\u201d) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of\u00a0$1.8 million\u00a0from the total grant of approximately\u00a0$7.4 million\u00a0from the National Institute on Drug Abuse\u00a0(\u201cNIDA\u201d), part of the National Institutes of Health (\u201cNIH\u201d), to support the development of OPNT003, nasal nalmefene, for the treatment of opioid overdose. The grant was awarded under award number 5U01DA046093-03. With the substantial increase in drug overdose deaths across the United States, primarily driven by rapid increases in overdose deaths involving synthetic opioids, including illicitly manufactured fentanyl1,\u00a0NIH leadership has highlighted the need for stronger, longer-acting formulations of antagonists to help prevent overdose … Continue reading \"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-31T20:04:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose","datePublished":"2021-03-31T20:04:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/"},"wordCount":665,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/","name":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=","datePublished":"2021-03-31T20:04:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIwOTcwNyM0MTAwOTY5IzIwMjAwNTY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/opiant-pharmaceuticals-announces-final-tranche-of-nida-grant-award-for-its-investigational-treatment-for-opioid-overdose\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468986","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=468986"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/468986\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=468986"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=468986"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=468986"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}